Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial
- DOI
- 10.1136/bmjopen-2025-109279
- Published
- 2026-08
- Container
- BMJ Open
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2025-109279,
title = {Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial},
author = {Enrique Seco-Meseguer and Stefan Stewart and Elena Diago-Sempere and Carlos Jiménez and Nicolas Macías Carmona and Juan Fernández Solís and Anna Vila Santandreu and Rosalía Valero San Cecilio and Verónica López Jiménez and Montserrat Carmona-Rodríguez and Luis A López-Fernández and Iñaki Imaz-Iglesia and María del Mar García-Saiz and Magí Farré and Consuelo Rodriguez-Jimenez and Judith Sanabria-Cabrera and Rocío Rosas-Alonso and Irene García-García and Alberto M Borobia},
year = {2026},
journal = {BMJ Open},
doi = {10.1136/bmjopen-2025-109279},
url = {https://doi.org/10.1136/bmjopen-2025-109279}
}RIS
TY - JOUR TI - Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial AU - Enrique Seco-Meseguer AU - Stefan Stewart AU - Elena Diago-Sempere AU - Carlos Jiménez AU - Nicolas Macías Carmona AU - Juan Fernández Solís AU - Anna Vila Santandreu AU - Rosalía Valero San Cecilio AU - Verónica López Jiménez AU - Montserrat Carmona-Rodríguez AU - Luis A López-Fernández AU - Iñaki Imaz-Iglesia AU - María del Mar García-Saiz AU - Magí Farré AU - Consuelo Rodriguez-Jimenez AU - Judith Sanabria-Cabrera AU - Rocío Rosas-Alonso AU - Irene García-García AU - Alberto M Borobia PY - 2026 JO - BMJ Open DO - 10.1136/bmjopen-2025-109279 UR - https://doi.org/10.1136/bmjopen-2025-109279 ER -
APA
Seco-Meseguer, E., Stewart, S., Diago-Sempere, E., Jiménez, C., Carmona, N. M., Solís, J. F., Santandreu, A. V., Cecilio, R. V. S., Jiménez, V. L., Carmona-Rodríguez, M., López-Fernández, L. A., Imaz-Iglesia, I., García-Saiz, M. D. M., Farré, M., Rodriguez-Jimenez, C., Sanabria-Cabrera, J., Rosas-Alonso, R., García-García, I., & Borobia, A. M. (2026). Multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of a pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort: iPHARMGx TRANSPGx nested clinical trial. BMJ Open. https://doi.org/10.1136/bmjopen-2025-109279
Source records
- crossref · retrieved 2026-11-10T14:47:35.921Z